| 1.74 0.06 (3.57%) | 06-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.86 | 1-year : | 3.6 |
| Resists | First : | 2.45 | Second : | 3.08 |
| Pivot price | 1.94  |
|||
| Supports | First : | 1.41 | Second : | 1.18 |
| MAs | MA(5) : | 1.73 |
MA(20) : | 2.2 |
| MA(100) : | 3.93 |
MA(250) : | 8.59 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 18.9 |
| RSI | RSI(14): 30.6 |
|||
| 52-week | High : | 29 | Low : | 1.41 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PPBT ] has closed above bottom band by 40.0%. Bollinger Bands are 49.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.77 - 1.78 | 1.78 - 1.79 |
| Low: | 1.61 - 1.62 | 1.62 - 1.63 |
| Close: | 1.73 - 1.74 | 1.74 - 1.75 |
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
Fri, 26 Jun 2026
Price to earnings forward of Purple Biotech Ltd. – TASE:PPBT - TradingView
Wed, 24 Jun 2026
PPBT SEC Filings - Purple Biotech Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Tue, 23 Jun 2026
Purple Biotech (NASDAQ: PPBT) details CAPTN-3 solid tumor pipeline and cash runway - Stock Titan
Thu, 11 Jun 2026
Purple Biotech (NASDAQ: PPBT) posts promising IM1240 preclinical data at EACR 2026 - Stock Titan
Thu, 11 Jun 2026
Purple cancer drug hits PD-1-resistant tumors, curbs cytokine surge in primates - Stock Titan
Wed, 20 May 2026
PPBT Stock Slides As Traders Weigh Deep Value Signals - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 925480 (%) |
| Held by Institutions | 3.7 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.6 % |
| Return on Equity (ttm) | -123.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.07 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.5 |
| Qtrly Earnings Growth | 226 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | 0.57 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.1 |
| Dividend | 0 |
| Forward Dividend | 101770 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|